By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) 

245 First Street
Suite 1800
Cambridge  Massachusetts  02142  U.S.A.
Phone: 503-227-0554 Fax: 503-227-0751



Company News
Sarepta (SRPT) To Announce Second Quarter 2015 Financial Results And Recent Corporate Developments On August 6, 2015 7/30/2015 11:06:24 AM
Sarepta (SRPT) Announces The New England Journal of Medicine Publication Of Phase I Clinical Data Of Marburg Drug Candidate, AVI-7288, Supporting Safety Of The Pmoplus Platform 7/23/2015 10:56:28 AM
Investors Gear Up For Exciting News as FDA Sets Dates for BioMarin (BMRN) and Sarepta (SRPT) DMD Drugs 7/21/2015 6:34:03 AM
Sarepta (SRPT) and BioMarin (BMRN) Rivalry Heats Up as Sarepta Shops for Second DMD Drug 7/14/2015 6:01:16 AM
Sarepta (SRPT) Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 7/1/2015 11:43:48 AM
Sarepta (SRPT) Bags Ex-Genzyme CEO as Advisor to the Company 7/1/2015 6:46:12 AM
New Sarepta (SRPT) CEO's Strategy Bears Fruit With NDA Filing 6/30/2015 6:24:24 AM
Sarepta (SRPT) Completes NDA Submission To FDA For Eteplirsen For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping 6/29/2015 12:44:38 PM
Sarepta (SRPT) Secures $40 Million In Debt Financing 6/29/2015 12:26:55 PM
EXCLUSIVE: Sarepta (SRPT)'s Interim CEO Doing Well Enough to Be Considered a Permanent Candidate, Company Tells BioSpace (DHX) 6/2/2015 8:08:56 AM